Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Feb 1.

Published in final edited form as: Am J Psychiatry. 2021 Aug 13;179(2):142–151. doi: 10.1176/appi.ajp.2021.21010032

Figure 2. — Sample Cases with Fluctuating and Recovery Patterns of Remission

Note. Case A demonstrated clinically significant impairment during the 2-year (age 9.42), 3-year age 11.11), 8-year (age 16.10), 10-year (age 17.87), and 16-year (age 24.11) assessments and was treated with methylphenidate during the 8-year assessment (age 16.10) and with atomoxetine during the 14-year assessment (age 21.76). Case B demonstrated clinically significant impairment during the 2-year (age 10.15) through 10-year (age 18.06 assessment) and was treated with methylphenidate during the 2-year, 3-year, and 6-year assessments (ages 10.15 through 14.31), classroom behavioral intervention for ADHD at the 3-year assessment (age 11.02), and attended a special school for ADHD at the 8-year assessment (age 16.28).

Figure 2. — Sample Cases with Fluctuating and Recovery Patterns of Remission

Note. Case A demonstrated clinically significant impairment during the 2-year (age 9.42), 3-year age 11.11), 8-year (age 16.10), 10-year (age 17.87), and 16-year (age 24.11) assessments and was treated with methylphenidate during the 8-year assessment (age 16.10) and with atomoxetine during the 14-year assessment (age 21.76). Case B demonstrated clinically significant impairment during the 2-year (age 10.15) through 10-year (age 18.06 assessment) and was treated with methylphenidate during the 2-year, 3-year, and 6-year assessments (ages 10.15 through 14.31), classroom behavioral intervention for ADHD at the 3-year assessment (age 11.02), and attended a special school for ADHD at the 8-year assessment (age 16.28).